Clovis Oncology Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Clovis Oncology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLVS, but not buy additional shares or sell existing shares.
View analyst ratings for Clovis Oncology or view top-rated stocks.

Wall Street analysts have given Clovis Oncology a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Clovis Oncology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Clovis Oncology is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Clovis Oncology.

Clovis Oncology will be holding an earnings conference call on Wednesday, August 4th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

Clovis Oncology (NASDAQ:CLVS) posted its quarterly earnings results on Wednesday, May, 5th. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.72) by $0.08. The biopharmaceutical company earned $38.05 million during the quarter, compared to analysts' expectations of $44.84 million.
View Clovis Oncology's earnings history.

Clovis Oncology's stock was trading at $6.17 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CLVS shares have decreased by 21.7% and is now trading at $4.83.
View which stocks have been most impacted by COVID-19.

4 equities research analysts have issued 12-month price targets for Clovis Oncology's shares. Their forecasts range from $3.00 to $12.00. On average, they anticipate Clovis Oncology's share price to reach $6.67 in the next twelve months. This suggests a possible upside of 38.0% from the stock's current price.
View analysts' price targets for Clovis Oncology or view top-rated stocks among Wall Street analysts.

12 employees have rated Clovis Oncology CEO Patrick J. Mahaffy on Glassdoor.com. Patrick J. Mahaffy has an approval rating of 49% among Clovis Oncology's employees. This puts Patrick J. Mahaffy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Clovis Oncology include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of CLVS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Tesla (TSLA), Amarin (AMRN), Intercept Pharmaceuticals (ICPT), Netflix (NFLX) and Alibaba Group (BABA).

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

Clovis Oncology's stock is owned by many different retail and institutional investors. Top institutional shareholders include Alliancebernstein L.P. (0.21%). Company insiders that own Clovis Oncology stock include Daniel W Muehl, Gillian C Ivers-Read, James C Blair, Lindsey Rolfe, Patrick J Mahaffy, Paul Edward Gross, Thomas C Harding and Thorlef Spickschen.
View institutional ownership trends for Clovis Oncology.

CLVS stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P.. Company insiders that have bought Clovis Oncology stock in the last two years include James C Blair, Patrick J Mahaffy, and Thorlef Spickschen.
View insider buying and selling activity for Clovis Oncology or or view top insider-buying stocks.

Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CLVS stock can currently be purchased for approximately $4.83.

Clovis Oncology has a market capitalization of $505.07 million and generates $164.52 million in revenue each year. The biopharmaceutical company earns $-369,210,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis.

The official website for Clovis Oncology is www.clovisoncology.com.

Clovis Oncology is headquartered at 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301.

Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]